- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 520-27-4] Diosmin
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-N0178 |
| Brand: | MCE |
| CAS: | 520-27-4 |
Overview
| MDL | MFCD00009772 |
|---|---|
| Molecular Weight | 608.54 |
| Molecular Formula | C28H32O15 |
| SMILES | O=C1C=C(C2=CC=C(OC)C(O)=C2)OC3=CC(O[C@H]4[C@@H]([C@H]([C@@H]([C@@H](CO[C@H]5[C@@H]([C@@H]([C@H]([C@H](C)O5)O)O)O)O4)O)O)O)=CC(O)=C13 |
2 Publications Citing Use of MCE
Summary
Diosmin is a flavonoid found in a variety of citrus fruits and also an agonist of the aryl hydrocarbon receptor ( AhR ).
IC50 & Target
AhR [1]
In Vitro
Treatment with Diosmin causes a dose dependent increase in the amount of adducts formed (up to a 7-fold increase in adducts at 5 μM Diosmin). At 5 μM, Diosmin increases the cytotoxicity of 7,12-dimethylbenz(a)anthracene (DMBA), shifting the IC 50 of DMBA from an estimated 1.2 μM to 400 nM. Diosmin is not cytotoxic in itself at the concentrations tested. Diosmin causes an increase in CYPIAI activity in MCF-7 cells in a time- and dose-dependent fashion. Diosmin causes a dose-dependent increase in CYPIAI mRNA after 24 h of incubation, causes a long-lasting increase in CYPIAI mRNA accumu lation that reaches its peak after 48 h of incubation [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Diosmin significantly decreases the malondialdehyde (MDA) levels and increases the activities of total-superoxide dismutase (T-SOD), glutathione peroxidase (GSH-Px), and catalase (CAT) in the retina of rats compare with the ischemia group (P<0.05), and suppresses the ischemia/reperfusion (I/R)-induced reduction in the a- and b-wave amplitudes of the electroretinograms (ERGs) (P<0.05). The thickness of the entire retina, inner nuclear layer, inner plexiform layer, and outer retinal layer and the number of cells in the ganglion cell layer are significantly less after I/R injury (P<0.05), and Diosmin remarkably ameliorates these changes on retinal morphology. Diosmin also attenuates the I/R-induced loss of retinal ganglion cells (RGCs) of the rat retina (P<0.05) [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT05626166 | Tanta University |
Ulcerative Colitis
|
November 2022 | Phase 3 |
| NCT02616731 | Ain Shams University |
Menorrhagia
|
September 2015 | Phase 1|Phase 2 |
| NCT03413618 | Pirogov Russian National Research Medical University |
Deep Vein Thrombosis|Postthrombotic Syndrome
|
December 20, 2017 | Phase 4 |
| NCT03471910 | Fundação Educacional Serra dos Órgãos |
Venous Insufficiency
|
June 20, 2017 | Phase 4 |
| NCT04358497 | Hospital de Clínicas Dr. Manuel Quintela|University of the Republic, Uruguay|Centro Cardiovascular Universitario|Centro Hospitalario Pereyra Rossell |
Pelvic Congestive Syndrome|Pelvic Varices|Venous Disease
|
October 1, 2020 | Phase 4 |
| NCT01532882 | Laboratoire Innotech International |
Chronic Venous Disease of Lower Limbs
|
January 2012 | Phase 3 |
| NCT02927483 | SunWave Pharma|Opera CRO, a TIGERMED Group Company |
Chronic Venous Insufficiency
|
November 2016 | Phase 3 |
| NCT02134249 | Benha University |
Infertility
|
April 2014 | Phase 2|Phase 3 |
| NCT04933591 | Pirogov Russian National Research Medical University |
Varicose Veins
|
September 1, 2020 | Not Applicable |
| NCT04452799 | Tanta University |
Coronavirus Infection
|
July 1, 2020 | Early Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 100 mg/mL ( 164.33 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.6433 mL | 8.2164 mL | 16.4328 mL |
| 5 mM | 0.3287 mL | 1.6433 mL | 3.2866 mL |
| 10 mM | 0.1643 mL | 0.8216 mL | 1.6433 mL |
References
- [1] Ciolino HP, et al. Diosmin and diosmetin are agonists of the aryl hydrocarbon receptor that differentially affectcytochrome P450 1A1 activity. Cancer Res. 1998 Jul 1;58(13):2754-60.
- [2] Tong N, et al. Diosmin protects rat retina from ischemia/reperfusion injury. J Ocul Pharmacol Ther. 2012 Oct;28(5):459-66.
Synonyms
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.